Prioritization schema for immunotherapy clinical trials in glioblastoma

Tiffany R. Hodges, Sherise D. Ferguson, Hillary G. Caruso, Gary Kohanbash, Shouhao Zhou, Timothy F. Cloughesy, Mitchel S. Berger, George H. Poste, Mustafa Khasraw, Sujuan Ba, Tao Jiang, Tom Mikkelson, W. K.Alfred Yung, John F. de Groot, Howard Fine, Lewis C. Cantley, Ingo K. Mellinghoff, Duane A. Mitchell, Hideho Okada, Amy B. Heimberger

Research output: Contribution to journalReview article

8 Scopus citations

Abstract

Background: Emerging immunotherapeutic strategies for the treatment of glioblastoma (GBM) such as dendritic cell (DC) vaccines, heat shock proteins, peptide vaccines, and adoptive T-cell therapeutics, to name a few, have transitioned from the bench to clinical trials. With upcoming strategies and developing therapeutics, it is challenging to critically evaluate the practical, clinical potential of individual approaches and to advise patients on the most promising clinical trials. Methods: The authors propose a system to prioritize such therapies in an organized and data-driven fashion. This schema is based on four categories of factors: antigenic target robustness, immune-activation and -effector responses, preclinical vetting, and early evidence of clinical response. Each of these categories is subdivided to focus on the most salient elements for developing a successful immunotherapeutic approach for GBM, and a numerical score is generated. Results: The Score Card reveals therapeutics that have the most robust data to support their use, provides a reference prioritization score, and can be applied in a reiterative fashion with emerging data. Conclusions: The authors hope that this schema will give physicians an evidence-based and rational framework to make the best referral decisions to better guide and serve this patient population.

Original languageEnglish (US)
Article numbere1145332
JournalOncoImmunology
Volume5
Issue number6
DOIs
StatePublished - Jun 2 2016

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Prioritization schema for immunotherapy clinical trials in glioblastoma'. Together they form a unique fingerprint.

  • Cite this

    Hodges, T. R., Ferguson, S. D., Caruso, H. G., Kohanbash, G., Zhou, S., Cloughesy, T. F., Berger, M. S., Poste, G. H., Khasraw, M., Ba, S., Jiang, T., Mikkelson, T., Yung, W. K. A., de Groot, J. F., Fine, H., Cantley, L. C., Mellinghoff, I. K., Mitchell, D. A., Okada, H., & Heimberger, A. B. (2016). Prioritization schema for immunotherapy clinical trials in glioblastoma. OncoImmunology, 5(6), [e1145332]. https://doi.org/10.1080/2162402X.2016.1145332